Altamira Therapeutics (Altamira Therapeutics) EV-to-Revenue

: -681.00 (As of Today)

View and export this data going back to 2014. Start your Free Trial

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Altamira Therapeutics's enterprise value is $2.72 Mil. Altamira Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.00 Mil. Therefore, Altamira Therapeutics's EV-to-Revenue for today is -681.00.

The historical rank and industry rank for Altamira Therapeutics's EV-to-Revenue or its related term are showing as below:

CYTO' s EV-to-Revenue Range Over the Past 10 Years
Min: 20.92 Med: 27.64 Max: 340.8
Current: -681

During the past 13 years, the highest EV-to-Revenue of Altamira Therapeutics was 340.80. The lowest was 20.92. And the median was 27.64.

CYTO's EV-to-Revenue is ranked worse than
100% of 1031 companies
in the Biotechnology industry
Industry Median: 7.58 vs CYTO: -681.00

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-19), Altamira Therapeutics's stock price is $1.42. Altamira Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.48. Therefore, Altamira Therapeutics's PS Ratio for today is 2.99.

Altamira Therapeutics EV-to-Revenue Historical Data

The historical data trend for Altamira Therapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Altamira Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Altamira Therapeutics Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-Revenue																-	-	-	-	-

Competitive Comparison

For the Biotechnology subindustry, Altamira Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Altamira Therapeutics EV-to-Revenue Distribution

For the Biotechnology industry and Healthcare sector, Altamira Therapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Altamira Therapeutics's EV-to-Revenue falls into.

Altamira Therapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Altamira Therapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	2.724	/	-0.004
	=	-681.00

Altamira Therapeutics's current Enterprise Value is $2.72 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Altamira Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.00 Mil.

Altamira Therapeutics (NAS:CYTO) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Altamira Therapeutics's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	1.42	/	0.475
	=	2.99

Altamira Therapeutics's share price for today is $1.42.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was $0.48.

Altamira Therapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Altamira Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Altamira Therapeutics (Altamira Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Altamira Therapeutics Ltd (NAS:CYTO) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

2 Church Street, Clarendon House, Hamilton, BMU, HM11

Website

https://www.altamiratherapeutics.com

Altamira Therapeutics Ltd is dedicated to developing therapeutics that address unmet medical needs. It is active in RNA therapeutics, allergy and viral infections, and inner ear disorders. Its product Bentrio is a drug-free nasal spray for personal protection against airborne viruses and allergens.